Insmed (INSM) Misses Q1 EPS by 1c, Revenues Miss

Insmed (NASDAQ: INSM) reported Q1 EPS of ($0.89), $0.01 worse than the analyst estimate of ($0.88). Revenue for the quarter came in at $40.21 million versus the consensus estimate of $41.64 million.

"Insmed is off to a strong start in 2021, with important advancements across each of our three programs and our earlier-stage research activities, as well as meaningful progress in the buildout of our global organization," commented Will Lewis, Chair and Chief Executive Officer of Insmed. "In the first quarter of the year, we were very pleased to secure approval of ARIKAYCE in Japan—the third major territory where our lead product is now approved. Despite the ongoing challenges of COVID-19, we demonstrated steady ARIKAYCE performance in the U.S. and advanced our European launch. We continue to enroll patients in both the Phase 3 ASPEN study of brensocatib in patients with bronchiectasis and the ARIKAYCE frontline clinical trial program in patients with NTM lung disease, and are working to advance TPIP to Phase 2 clinical development. I am very proud of the Insmed team's steadfast dedication to the ambitious patient-centered vision we have set for this company."

For earnings history and earnings-related data on Insmed (INSM) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Myriad Genetics board member Skovronsky resigns
• Insmed (INSM) PT Lowered to $160 at Evercore ISI